Navigation Links
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

ons (NDAs) and supplemental NDAs (sNDAs). He joins Sunesis from Reliant Pharmaceuticals, Inc., where he served as Senior Vice President, Research & Development and Medical Affairs. In this role, he was responsible for the strategic direction and day-to-day operations, as well as the organizational growth, of Reliant's clinical R&D and product development capabilities. Previously, Dr. Ketchum served as Senior Vice President, Operations and Regulatory Affairs for IntraBiotics Pharmaceuticals, Inc. from 2002 to 2005, where he was responsible for regulatory affairs, project management, quality assurance, and supply chain management in support of late-stage clinical research. Dr. Ketchum also held positions of increasing responsibility in regulatory affairs during his nearly eight-year tenure at ALZA Corporation from 1994 to 2002, most recently as Senior Director, Regulatory Affairs. He earned a Ph.D. in Pharmacology from University College London (funded by the Sandoz Institute for Medical Research) and a B.S. in Biological Sciences from Stanford University.

Over the past year, Dr. Bolton has served as a consultant to Sunesis on the development of voreloxin. As a medical oncologist, she brings more than a decade of industry experience in the clinical development of oncology therapeutics to her new post as Vice President, Clinical Development. From 2004 to 2005, Dr. Bolton was Vice President, Clinical Development for Sonus Pharmaceuticals, Inc. responsible for Phase 1-3 clinical development of the company's lead molecule. Before that, she served as Medical Director with ZymoGenetics, Inc. and as Medical Director for Cell Therapeutics, Inc., leading each company's clinical development programs and providing input on regulatory strategy. From 1999 to 2001, Dr. Bolton led the Herceptin(R) post-marketing team at Genentech, Inc., where she served as a Clinical Scientist. Prior to her industry experience, Dr. Bolton spent several years as a practicing oncologist, most r
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
(Date:9/16/2014)... 2014 According to Jeff Howell, Partner ... ITRA Global, new development in Downtown Toronto is expanding ... approving another 755 storeys of new development last week ... will be dominating the Toronto skyline for the foreseeable ... unquenchable thirst for new development. , As the Toronto ...
(Date:9/15/2014)... SYDNEY , Sept. 15, 2014 ... focused on revolutionizing the treatment of cancer through ... cancer cells, announced that, together with the Asbestos ... 2014 Cancer Institute New South Wales (NSW) Premier,s ... other four recipients are the hospitals that will ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
Breaking Biology Technology:LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... France, April 23 , - ... Essilor International, the world leader in ophthalmic optics, today,announced ... 31, 2009, representing a reported 10.3% increase on the first ... the period. , Despite contracting demand ...
... RICHMOND, Calif., April 22 Sangamo BioSciences, Inc. (Nasdaq: ... will release its first quarter 2009 financial results on ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ...
... to Discuss Results to Be Held at 9:00 A.M. - ... VPHM ) first quarter financial results for 2009 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 3ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2
(Date:9/15/2014)... on Earth for the first 500 million years after ... present day, complete with oceans, continents and active crustal ... eon, called the Hadean, has gained substantial new support ... formed more than 4 billion years ago with those ... a possible geological analog for early Earth. , The ...
(Date:9/15/2014)... are hallmarks of the cheetah: The big predator is the ... mph in just a few seconds. As it ramps up ... bounding until it reaches a full gallop. , Now MIT ... implemented in a robotic cheetah a sleek, four-legged assemblage ... much as its feline counterpart. The team recently took the ...
(Date:9/15/2014)... who transplanted combinations of wild, domesticated, and ... to new environments found that within 5 ... foreign genes from wild populations that hybridized ... Applications study provides evidence that natural ... that hybridized populations experience as a result ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Run, cheetah, run 2Run, cheetah, run 3
... how the brain controls breathing is fundamental to the ... an automatic rhythmic process that persists without conscious effort ... that has intrigued many scientists for well over 100 ... rhythm throughout life? , Experimental Physiology editor Julian Paton ...
... sudden changes in water quality, creation of coastal "dead ... climate are just some of the potential consequences of ... new United Nations-backed report launched today. , Humans have ... 50 years than in any other period, some 60 ...
... can survive an otherwise lethal dose of vaccinia virus, ... the National Institute of Allergy and Infectious Diseases (NIAID), ... say the investigators, suggest that Gleevec or similar drugs ... smallpox vaccine. The classic smallpox vaccine is made from ...
Cached Biology News:How exactly does the brain control breathing? 2UN: World in big ecological mess 2UN: World in big ecological mess 3Cancer drug slows poxvirus in mice 2Cancer drug slows poxvirus in mice 3
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Biology Products: